Predictive Oncology Files 8-K with Material Agreement
Ticker: AGPU · Form: 8-K · Filed: Jan 6, 2025 · CIK: 1446159
Sentiment: neutral
Topics: material-agreement, company-name-change
TL;DR
Predictive Oncology signed a new deal, filing an 8-K on Jan 1, 2025.
AI Summary
Predictive Oncology Inc. filed an 8-K on January 6, 2025, reporting a material definitive agreement. The filing also includes financial statements and exhibits. The company was formerly known as Skyline Medical Inc. before changing its name on August 7, 2013.
Why It Matters
This filing indicates a significant new agreement for Predictive Oncology, which could impact its business operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, requiring further analysis of the agreement's terms.
Key Players & Entities
- Predictive Oncology Inc. (company) — Registrant
- January 1, 2025 (date) — Earliest event reported
- January 6, 2025 (date) — Date of report
- Skyline Medical Inc. (company) — Former company name
- August 7, 2013 (date) — Date of name change from Skyline Medical Inc.
FAQ
What is the nature of the material definitive agreement filed by Predictive Oncology Inc.?
The filing indicates a material definitive agreement was entered into, but the specific details of the agreement are not provided in this summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on January 1, 2025.
What is the filing date of this 8-K report?
The 8-K report was filed on January 6, 2025.
What was Predictive Oncology Inc. previously named?
Predictive Oncology Inc. was formerly known as Skyline Medical Inc.
When did the company change its name from Skyline Medical Inc.?
The company changed its name from Skyline Medical Inc. on August 7, 2013.
Filing Stats: 796 words · 3 min read · ~3 pages · Grade level 11.7 · Accepted 2025-01-06 17:00:11
Key Financial Figures
- $0.01 — ange on which registered Common stock, $0.01 par value POAI Nasdaq Capital Market
- $3.00 — d stock is automatically redeemable for $3.00 per share after 18 months and may also
- $4.50 — o's common stock has traded at or above $4.50 per share for 30 consecutive trading da
- $1.07 — f Predictive Oncology's common stock at $1.07 per share. The parties have agreed to e
- $15 million — is subject to a minimum fundraising of $15 million by Renovaro, as well as formal approval
Filing Documents
- f8k_010625.htm (8-K) — 17KB
- exh_101.htm (EX-1.01) — 24KB
- exh_991.htm (EX-99.1) — 9KB
- 0001171843-25-000051.txt ( ) — 258KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_010625_htm.xml (XML) — 3KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement. On January 6, 2025, Predictive Oncology Inc. issued a press release attached hereto as Exhibit 99.1 announcing that it has entered into a binding letter of intent with Renovaro, Inc. (NASDAQ: RENB) ("Renovaro") for Predictive Oncology to be acquired by Renovaro in exchange for preferred stock of Renovaro. Under the terms of the binding letter of intent, Predictive Oncology will be merged into Renovaro in exchange for a newly created series of preferred stock of Renovaro. The preferred stock will be issued to shareholders of Predictive Oncology in a 1:1 exchange for their existing Predictive Oncology common stock. The preferred stock is automatically redeemable for $3.00 per share after 18 months and may also be converted to freely tradeable, registered Renovaro common stock at a 1:1 conversion ratio by either the holders thereof or Renovaro at any time after Renovaro's common stock has traded at or above $4.50 per share for 30 consecutive trading days. Renovaro also has the right to redeem the preferred stock for cash at a redemption price of $3.00 per share (i) if the trading price of its common stock is $3.00 or less or (ii) such preferred stock has not been converted within 30 days after the first date on which the holder could request such conversion as described above. Notwithstanding the foregoing, if holders of Predictive Oncology's Series A and Series B warrants do not exercise their warrants before January 15, 2025, Renovaro has agreed to purchase up to 2.33 million shares of Predictive Oncology's common stock at $1.07 per share. The parties have agreed to enter into definitive documentation for the merger by no later than February 28, 2025. The merger is subject to a minimum fundraising of $15 million by Renovaro, as well as formal approval by the shareholders of Predictive Oncology. A failure to obtain shareholder approval, assuming prior funding by Renovaro, will entitle Renovaro to a two-year excl
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 1.01 Letter of Intent between Predictive Oncology and Renovaro 99.1 Predictive Oncology Announces Agreement to be Acquired by Renovaro 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Predictive Oncology Inc. Date: January 6, 2025 By: /s/ Josh Blacher Josh Blacher Interim Chief Financial Officer